An NR2B-specific NMDA antagonist with a unique mechanism of action tested in >375 subjects to date.


Targeting Neurogenic Orthostatic Hypotension (nOH)

CERC-301 is a selective NR2B-specific NMDA receptor antagonist being developed for the treatment of Neurogenic Orthostatic Hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy and Pure Autonomic Failure. CERC-301 has a novel mechanism of action with rapid onset to effect. We believe these attributes may result in improved efficacy and long-term effectiveness with fewer side effects than the leading nOH treatments currently available.

of CERC-301

  • Rapid onset of action
  • Robust blood pressure effect with favorable side-effect profile
  • Oral formulation

About nOH

Neurogenic Orthostatic Hypotension (nOH) is associated with neurodegenerative diseases such as Parkinson's Disease (PD), Multiple Systems Atrophy (MSA), and Pure Autonomic Failure (PAF).1

It is estimated that less than 200,000 patients suffer from PD-associated nOH in the U.S, thus qualifying as a rare disease eligible for Orphan Drug Designation with the FDA.2

nOH is due to a failure of the autonomic nervous system to prevent blood pooling in lower extremities upon standing, causing a fall in blood pressure and symptoms such as dizziness/lightheadedness/feeling faint, weakness, blurry vision, head and neck pain, fatigue, and syncope.


1. Metzler, M et al. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol 2013;260 (9):2212-2219.
2. . Kaufmann, H et al. Neurogenic orthostatic hypotension: the very basics. Clin Auton Res 2017;27 (suppl 1):39-43.
3. Freeman, R. Neurogenic Orthostatic Hypotension. N Engl J Med 2008;358:615-624.

Mechanism of Action

NR2B specific NMDA antagonist

CERC-301 is an orally available, NR2B-specific, NMDA receptor antagonist. NMDA receptor overactivation is associated with many neurodegenerative diseases, including Parkinson's disease. The neural-protective attributes of NMDA receptors antagonists, such as CERC-301, may provide a therapeutic benefit to patients with neurodegenerative conditions. Further investigations to fully understand the therapeutic benefits of NMDA receptor antagonists and the exact mechanism of action of CERC-301 are ongoing.